Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies

OBJECTIVE: The Psoriatic Arthritis Long-term Assessment of Clinical Efficacy (PALACE) clinical trial programme findings demonstrated that apremilast, an oral phosphodiesterase 4 inhibitor, is effective for treating psoriatic arthritis (PsA). Enthesitis and dactylitis are difficult-to-treat features...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:RMD Open
Autores principales: Gladman, Dafna D, Kavanaugh, Arthur, Gómez-Reino, Juan J, Wollenhaupt, Jürgen, Cutolo, Maurizio, Schett, Georg, Lespessailles, Eric, Guerette, Benoit, Delev, Nikolay, Teng, Lichen, Edwards, Christopher J, Birbara, Charles A, Mease, Philip J
Formato: Artigo
Lenguaje:Inglês
Publicado: BMJ Publishing Group 2018
Materias:
Psoriatic Arthritis
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6045740/
https://ncbi.nlm.nih.gov/pubmed/30018799
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2018-000669
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares